Publications by authors named "O Perez-Martinez"
Introduction: Our aim was to estimate the risk of pneumonia, admission to intensive care unit (ICU) or death in individuals ≥65 years old admitted to hospital with RSV, compared to influenza or COVID-19.
Methods: We included hospitalised patients from Severe Acute Respiratory Infection Surveillance in Spain between 2021-2024, aged ≥65 years, laboratory confirmed for RSV, influenza or SARS-CoV-2. Using a binomial regression with logarithmic link, we estimated the relative risk (RR) of pneumonia, ICU admission and in-hospital mortality, in patients with RSV compared to influenza or SARS-CoV-2, adjusting for age, sex, season and comorbidities.
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Narmeen Mallah Sonia Ares-Gómez Jacobo Pardo-Seco Alberto Malvar-Pintos María-Isolina Santiago-Pérez
Hum Vaccin Immunother
December 2024
Article Synopsis
- Nirsevimab has been approved for universal RSV prevention in infants, with a study (NIRSE-GAL) launched in Galicia in September 2023 to assess its effectiveness against various RSV-related health issues.
- The study will monitor infants during the RSV season, focusing on different groups including newborns and those at high risk, and will track outcomes until significant events occur or the study concludes.
- Data analysis will utilize sophisticated models and will include safety monitoring of nirsevimab, with results communicated through scientific publications and conferences.
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
Clara Mazagatos Jacobo Mendioroz Mercedes Belén Rumayor Virtudes Gallardo García Virginia Álvarez Río
Influenza Other Respir Viruses
May 2024
Article Synopsis
- The study analyzed data from Spain's surveillance system for severe acute respiratory infections to assess the effect of nirsevimab on infants born from April 1, 2023, onward.
- Researchers compared actual RSV hospitalizations in children under one year old from late 2023 to early 2024 with expected numbers based on previous seasons.
- The results showed a significant reduction in hospitalizations, estimating between 9,364 to 9,875 fewer cases, which represents a 74% to 75% decrease in RSV-related hospitalizations.
Article Synopsis
- Galicia, Spain, launched a program in September 2023 to give nirsevimab for RSV prevention in infants, focusing on newborns, those under 6 months, and high-risk children aged 6-24 months.
- The interim analysis of the study, using data from Sept 25 to Dec 31, 2023, assesses nirsevimab's effectiveness in preventing different levels of RSV-related hospitalizations and complications.
- The study compares the results with data from previous RSV seasons to calculate how many cases of hospitalization were potentially avoided due to the immunization campaign.